Creative Planning
EDIT icon

Creative Planning’s Editas Medicine EDIT Stock Holding History

Creative Planning’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Buy
45,572
+22,488
+97% +$65.7K ﹤0.01% 3966
2026
Q1 		$57K Buy
+23,084
New +$48.9K ﹤0.01% 3973
2024
Q4 		– Sell
-21,563
Closed -$73.5K – 3618
2024
Q3 		$73.5K Buy
21,563
+11,473
+114% +$49.9K ﹤0.01% 3056
2024
Q2 		$47.1K Buy
+10,090
New +$56.9K ﹤0.01% 2929
2022
Q2 		– Sell
-250
Closed -$5K – 2357
2022
Q1 		$5K Buy
+250
New +$4.65K ﹤0.01% 2243
2021
Q3 		– Sell
-3,736
Closed -$212K – 2140
2021
Q2 		$212K Sell
3,736
-13,299
-78% -$491K ﹤0.01% 1779
2021
Q1 		$715K Buy
17,035
+5,634
+49% +$321K ﹤0.01% 1219
2020
Q4 		$799K Sell
11,401
-3,968
-26% -$163K ﹤0.01% 1057
2020
Q3 		$431K Sell
15,369
-28
-0.2% -$912 ﹤0.01% 1208
2020
Q2 		$455K Sell
15,397
-22,670
-60% -$592K ﹤0.01% 1080
2020
Q1 		$755K Sell
38,067
-12,505
-25% -$315K ﹤0.01% 752
2019
Q4 		$1.5M Buy
50,572
+17,758
+54% +$444K ﹤0.01% 622
2019
Q3 		$746K Sell
32,814
-750
-2% -$18.6K ﹤0.01% 874
2019
Q2 		$830K Buy
33,564
+7,060
+27% +$169K ﹤0.01% 839
2019
Q1 		$648K Buy
26,504
+1,879
+8% +$42.5K ﹤0.01% 911
2018
Q4 		$560K Sell
24,625
-233
-0.9% -$6.34K ﹤0.01% 903
2018
Q3 		$791K Buy
24,858
+28
+0.1% +$905 ﹤0.01% 862
2018
Q2 		$890K Sell
24,830
-1,227
-5% -$43.4K ﹤0.01% 808
2018
Q1 		$864K Buy
26,057
+2,532
+11% +$90.2K ﹤0.01% 807
2017
Q4 		$723K Buy
23,525
+14,318
+156% +$361K ﹤0.01% 881
2017
Q3 		$221K Buy
9,207
+106
+1% +$2.02K ﹤0.01% 1526
2017
Q2 		$153K Buy
9,101
+9,000
+8,911% +$162K ﹤0.01% 1678
2017
Q1 		$2K Sell
101
-3,339
-97% -$69.2K ﹤0.01% 4272
2016
Q4 		$56K Buy
3,440
+3,439
+343,900% +$52.2K ﹤0.01% 2303
2016
Q3 		$0 Sell
1
-1,600
-100% -$32.8K ﹤0.01% 4605
2016
Q2 		$39K Buy
1,601
+1,200
+299% +$40.5K ﹤0.01% 2313
2016
Q1 		$14K Buy
+401
New +$10.5K ﹤0.01% 3003

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Creative Planning's EDIT Position: Q2 2026 in Review

Creative Planning increased its Editas Medicine (EDIT) stake by 97% in Q2 2026, buying an estimated $65.7K and bringing the position to 45,572 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #3966.

Creative Planning first reported a position in EDIT in Q1 2016 and has held it in 27 quarters since. The position peaked at $1.5M in Q4 2019. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Creative Planning held 45,572 shares of Editas Medicine worth $148K as of Q2 2026.
  • Creative Planning bought 22,488 Editas Medicine shares in Q2 2026, an estimated $65.7K.
  • Editas Medicine made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3966 holding.
  • Creative Planning first reported a position in Editas Medicine in Q1 2016 and has held it in 27 quarters since.
  • Creative Planning's Editas Medicine position peaked at $1.5M in Q4 2019.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.